UroGen Pharma Ltd
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
URGN$24.75-3.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
FINANCIAL INFORMATION Financial Statements (Unaudited)Condensed Consolidated Balance Sheets
Part I**—Financial Information
Item 1. Financial Statements.
UroGen Pharma Ltd.
Condensed Consolidated Balance Sheets
(unaudited; in thousands, except share amounts and par value)
| September 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $124,916 | $95,002 |
| Marketable securities | 124,659 | 41,966 |
| Restricted cash | 1,073 | 821 |
| Accounts receivable, net | 22,802 | 15,443 |
| Inventories | 7,594 | 5,673 |
| Prepaid expenses and other current assets | 14,053 | 10,281 |
| Total current assets | 295,097 | 169,186 |
| Non-current assets: | ||
| Property and equipment, net | 608 | 689 |
| Restricted deposit | 175 | 225 |
| Right of use assets | 1,052 | 1,671 |
| Marketable securities | 4,641 | 4,502 |
| Other non-current assets | 370 | 2,038 |
| Total Assets | $301,943 | $178,311 |
| Liabilities and Shareholders' Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $19,685 | $16,538 |
| Employee related accrued expenses | 9,029 | 10,814 |
| Other current liabilities | 4,073 | 3,860 |
| Total current liabilities: | 32,787 | 31,212 |
| Non-current liabilities: | ||
| Prepaid forward obligation | 118,526 | 109,722 |
| Long-term debt | 121,709 | 98,551 |
| Long-term lease liabilities | 212 | 844 |
| Uncertain tax positions liability | 3,194 | 3,194 |
| Total Liabilities | 276,428 | 243,523 |
| Commitments and Contingencies (Note 18) | ||
| Shareholders' Equity (Deficit): | ||
| Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at September 30, 2024 and December 31, 2023; 42,190,815 and 32,490,119 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 115 | 89 |
| Additional paid-in capital | 793,874 | 614,035 |
| Accumulated deficit | (768,710) | (679,348) |
| Accumulated other comprehensive income | 236 | 12 |
| Total Shareholders' Equity (Deficit) | 25,515 | (65,212) |
| Total Liabilities and Shareholders' Equity (Deficit) | $301,943 | $178,311 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.